Fintel reports that Vivo Opportunity has filed a 13G/A form with the SEC disclosing ownership of 2.25MM shares of Avadel Pharmaceuticals plc ( AVDL ). This represents 3.6% of the company. In their previous filing dated February 11, 2022 they reported 2.40MM shares and 4.10% of the company, a decrease in shares of 6.23% and a decrease in total ownership of 0.50% (calculated as current – previous percent ownership). Analyst Price Forecast Suggests 56.97% Upside As of February 13, 2023, the average one-year price target for Avadel Pharmaceuticals is $12.70. The forecasts range from a low of $7.07 to a high of $19.95. The average price target represents an increase of 56.97% from its latest reported closing price of $8.09. The projected annual revenue for Avadel Pharmaceuticals is $23MM, an increase of ∞%. The projected annual EPS is -$1.08. What is the Fund Sentiment? There are 93 funds or institutions reporting positions in Avadel Pharmaceuticals. This is a decrease of 8 owner(s) or 7.92% in the last quarter. Average portfolio weight of all funds dedicated to AVDL is 0.23%, an increase of 84.45%. Total shares owned by institutions decreased in the last three months by 13.14% to 30,770K shares. […]
K&X Design and Investment Technology, LLC
Invest The Invisible Impact
K&X Design and Investment Technology, LLC
Invest The Invisible Impact
